Evidence map›Paper›PMID 40847235›Full record

ReviewCancer treatment and research2025

Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.

Pankaj Garg, Gargi Singhal, Siddhika Pareek, Ajaz Khan, TingTing Tan, Deric Wheeler, Sharad S Singhal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pankaj GargDepartment of Chemistry, GLA University, Mathura, Uttar Pradesh, India.
Gargi SinghalUndergraduate Medical Sciences, S.N. Medical College Agra, Agra, Uttar Pradesh, India.
Siddhika PareekDepartment of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Ajaz KhanDepartment of Medical Oncology, Zion, IL, USA.
TingTing TanDepartment of Medical Oncology, City of Hope National Medical Center, Newport Beach, CA, USA.
Deric WheelerDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Sharad S SinghalDepartment of Medical Oncology & Therapeutics Research, Beckman Research Institute, City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA. ssinghal@coh.org.ORCID https://orcid.org/0000-0002-6415-8160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) remains one of the most challenging gynecologic malignancies due to its late-stage diagnosis, high recurrence rates, and limited survival outcomes. Immunotherapy has emerged as a transformative approach in cancer treatment, leveraging the immune system to target tumor cells. This chapter provides a comprehensive overview of immunotherapy in OC, discussing its mechanisms, key strategies, and clinical advancements. Key areas include the role of immune checkpoint inhibitors (ICIs), adoptive cell therapies (ACT), cancer vaccines, and oncolytic viruses. Despite promising preclinical and clinical outcomes, significant challenges persist, including low immunogenicity, resistance mechanisms, and immune-related adverse events. Strategies to address these barriers, such as combination therapies, biomarker-guided approaches, and the integration of artificial intelligence (AI) for personalization, are discussed. Emerging directions, including next-generation immune checkpoint targets and innovations in epigenetic and metabolic reprogramming, are explored to envision the future of immunotherapy in OC. By addressing these challenges and leveraging innovative strategies, immunotherapy has the potential to redefine the therapeutic landscape, improving survival and quality of life for patients with OC.

Indexed as

ImmunotherapyOvarian NeoplasmsFemaleHumansImmune Checkpoint InhibitorsImmune Checkpoint InhibitorsChemotherapyImmune checkpoint inhibitorsImmune suppressive cellsImmunotherapyOncolytic virusesOvarian cancerTargeted therapyTumor microenvironment

Identifiers

PMID40847235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.